Connecting Investors and Business Leaders to Accelerate Cancer Innovation

Join us for an exclusive gathering of senior-level investors, corporate executives, entrepreneurs, and business leaders at the Third Annual Oncology Venture, Innovation & Partnering Summit, October 19-20, 2026, in Cambridge, MA. Connect with future investors and partners at intimate networking sessions; gain strategic insights on funding activities, exits, business development, and innovation strategies in cancer therapeutics and diagnostics from industry-led panels; and hear candid perspectives and business recommendations from oncology thought leaders during dynamic fireside chats. The Oncology Venture, Innovation & Partnering Summit is positioned as the premier meeting place for key oncology stakeholders to foster meaningful connections, acquire valuable strategic insights, and drive innovation and collaboration

EVENT FEATURES:

Network with investors, CEOs, and pharma leaders at exclusive receptions and networking events
Gather actionable insights from oncology business leaders during engaging panel discussions
Strategize for commercial success and learn from oncology executives at fireside chats
Brainstorm most timely topics and meet future partners and investors at targeted roundtables
Learn the latest innovations in technology showcases
Join the annual meeting and accelerate cancer innovation!

AGENDA

SPEAKERS

DOWNLOADS

2025 Featured Speakers

Mara Aspinall

Partner
Illumina Ventures

Benjamin Auspitz

Managing Partner, Breakout Fund
Curie.Bio

Jamil M. Beg

Partner
SV Health Investors

Christine Brennan

Managing Director
Vertex Ventures HC

Polly Brown

Vice President & Head, Business Development
AstraZeneca

Christopher M. Coburn

CIO
Mass General Brigham

Stephen J. Curtis

Senior Director, New Ventures
BrightEdge, American Cancer Society

Derek DiRocco

Partner
RA Capital Management

Keith T. Flaherty

Director, Clinical Research
MGH Cancer Center

Anna French

Managing Partner
Qiming Venture Partners

Munir Ghesani

CMO
United Theranostics

Brian Goodman

Managing Director
Vida Ventures

Chelsea Place Johnson

Principal
Atlas Venture

Jeff Jones

Managing Director, Equity Research
Oppenheimer & Co., Inc.

Peter Kolchinsky

Managing Partner
RA Capital Management

Manoja Lecamwasam

System Vice President
CommonSpirit Health

Lizabeth Leveille

Vice President & Head, Boston & European Innovation Hubs
Merck

Nils Lonberg

CEO
Tripeaks Therapeutics

Shiva Malek

Global Head, Oncology Disease Area
Novartis BioMedical Research

Melissa McCracken

Partner
Nextech Ventures LLC

Tom Miller

Founder & Managing Partner
GreyBird Ventures, LLC

Aaron Nelson

Partner, Venture Investments
Novo Holdings US

Kendalle O'Connell

CEO & President
MassBio

Michael Partsch

Chief Venture Officer
Wisconsin Alumni Research Foundation

Marie-Claire Peakman

Partner
Pfizer Ventures

Michal Preminger

Former Regional Head, East North America
Johnson & Johnson Innovation

Daniel Pryma

Vice President, Global Clinical Development
Eli Lilly and Company

Bob Radinsky

Vice President & Global Head, Oncology External Innovation
Johnson & Johnson Innovative Medicines

Victoria Richon

CEO
Entact Bio

Matthew Roden

President & CEO
Aktis Oncology

Jason Ruth

Vice President & Sector Lead, Biotech Private Investments
Wellington Management

Catherine Sabatos-Peyton

CEO
Larkspur Biosciences, Inc.

Maya R. Said

Founder & CEO
Outcomes4Me

David Stevenson

COO & Managing Director
Merck Global Health Innovation Fund

Laura Tadvalkar

Managing Director
RA Capital Management

Darshana Zaveri

Founder and Managing Partner
Catalyst Health Ventures

View All Speakers

2026 Agenda Topics Include

Investing Opportunities and Outlook for Oncology Innovation in 2026
Leading through Uncertainty: Oncology CEO Perspectives
Scientific Breakthroughs Driving Oncology Innovation
Opportunities and Challenges in Partnering with Pharma
Cancer Research and Academic Innovation

Supporting Patient Journey: Innovation Opportunities
Oncology Therapeutic Development Platforms
Precision Medicine and Diagnostics
Opportunities for Artificial Intelligence to Transform Drug Development and Healthcare